Crenigacestat (LY3039478)

Catalog No.S7169

For research use only.

Crenigacestat (LY3039478) is an oral Notch and gamma-secretase inhibitor with IC50 of 0.41 nM for Notch.

Crenigacestat (LY3039478) Chemical Structure

CAS No. 1421438-81-4

Selleck's Crenigacestat (LY3039478) has been cited by 16 publications

Purity & Quality Control

Choose Selective Notch Inhibitors

Biological Activity

Description Crenigacestat (LY3039478) is an oral Notch and gamma-secretase inhibitor with IC50 of 0.41 nM for Notch.
Targets
Notch [1]
~1 nM
In vitro

LY3039478 is a novel small molecule that is an exquisitely potent inhibitor of Notch-1 intracellular domain (N1ICD) cleavage with an IC50 of ∼1nM in most of the tumor cell lines tested. LY3039478 also potently inhibits mutant Notch receptor activity[2]. Treatment with a gamma secretase inhibitor, LY3039478, significantly inhibited the growth of 2 CCRCC(Clear cell renal cell carcinoma) cell lines in a concentration dependent manner. LY3039478 treatment also led to decreased expression of Myc and Cyclin A1, two genes that were part of the NOTCH driven proliferative signature in murine and human model systems. LY3039478 treatment also led to G0/G1 cell cycle arrest in CCRCC cells[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SW480 NV3kdZhvTnWwY4Tpc44h[XO|YYm= NE\UZW8zPCCqcoO= MkDCTY5pcWKrdHnvckBw\iCpYX3tZU1{\WO{ZYThd4UhdWWmaXH0[YQh[2ynYY\h[4Uhd2ZiTn;0Z4ghOSCrbjDoeY1idiCVV{S4NEBk\WyuczDhd5Nme3OnZDDhd{BvfWOuZXHyJIFk[3WvdXzheIlwdiCxZjDOc5RkcCBzIHnueJJi[2WubIXsZZIh\G:vYXnuJEhPOUmFRDmgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yMECxJO69VS5? NETLU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4QCd-MkS5NFA3Pzh:L3G+
HEL 92.1.7 M1TBU2Z2dmO2aX;uJIF{e2G7 NEHXeGEzPCCqcoO= M2HrRWlvcGmkaYTpc44hd2ZiZ3HtcYEue2WlcnX0ZZNmKG2nZHnheIVlKGOuZXH2ZYdmKG:oIF7veINpKDFiaX6gbJVu[W5iSFXMJFkzNjFwNzDj[YxteyCjc4Pld5Nm\CCjczDueYNt\WG{IHHjZ5VufWyjdHnvckBw\iCQb4TjbEAyKGmwdILhZ4VtdHWuYYKg[I9u[WmwIDjONWlETCliYX\0[ZIhOjRiaILzJIJ6KEWOSWPBMEBKSzVyIE2gNE4xODB{MzFOwG0v NXnjTFRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzhpPkK0PVAxPjd6PD;hQi=>
U-87-MG NWnhOmdQTnWwY4Tpc44h[XO|YYm= NYnYUnlVOjRiaILz NUm2dmFuUW6qaXLpeIlwdiCxZjDnZY1u[S2|ZXPy[ZRie2VibXXkbYF1\WRiY3zlZZZi\2Vib3[gUo91[2hiMTDpckBpfW2jbjDVMVg4NU2JIHPlcIx{KGG|c3Xzd4VlKGG|IH71Z4xm[XJiYXPjeY12dGG2aX;uJI9nKE6xdHPoJFEhcW62cnHj[YxtfWyjcjDkc41icW5iKF6xTWNFMSCjZoTldkAzPCCqcoOgZpkhTUyLU1GsJGlEPTBiPTCwMlAxODJ6IN88UU4> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[3PEc,OjR7MEC2O|g9N2F-
BxPC3 M321NWZ2dmO2aX;uJIF{e2G7 NULTUW9YOjRiaILz NGnId2NKdmirYnn0bY9vKG:oIHfhcY1iNXOnY4LleIF{\SCvZXTpZZRm\CClbHXheoFo\SCxZjDOc5RkcCBzIHnuJIh2dWGwIFL4VGM{KGOnbHzzJIF{e2W|c3XkJIF{KG63Y3zlZZIh[WOldX31cIF1cW:wIH;mJG5wfGOqIEGgbY51emGlZXzseYxieiCmb33hbY4hME5zSVPELUBi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSByLkCwNFM6KM7:TT6= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[3PEc,OjR7MEC2O|g9N2F-
HEK293deltaE12 NXy2VVY3TnWwY4Tpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGejbX3hMZNm[3KndHHz[UBu\WSrYYTl[EBkdGWjdnHn[UBw\iC2cnHud4Zm[3SnZDDtc5V{\SCQb4TjbEAyKChzN{CzMVIyQDNrIHjhdoJwemmwZzDOMZRmem2rbnHsJFI{KGGvaX7vZYNq\CC|aXfuZYwheGWydHnk[UB{\XG3ZX7j[UBqdiCqdX3hckBJTUt{OUPk[Yx1[UVzMjDj[YxteyCjc4Pld5Nm\CCjczDueYNt\WG{IHHjZ5VufWyjdHnvckBw\iCQb4TjbEAyKGmwdILhZ4VtdHWuYYKg[I9u[WmwIDjONWlETCliYX\0[ZItKEmFNUCgQUAxNjByMESxJO69VS5? NYDhSYd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzhpPkK0PVAxPjd6PD;hQi=>
A375 NYn3XllKTnWwY4Tpc44h[XO|YYm= MnjoNlQhcHK| NHrHb2hKdmirYnn0bY9vKG:oIHfhcY1iNXOnY4LleIF{\SCvZXTpZZRm\CClbHXheoFo\SCxZjDOc5RkcCBzIHnuJIh2dWGwIFGzO|Uh[2WubIOgZZN{\XO|ZXSgZZMhdnWlbHXhdkBi[2O3bYXsZZRqd25ib3[gUo91[2hiMTDpcpRz[WOnbHz1cIFzKGSxbXHpckApVjGLQ1SpJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiSVO1NEA:KDBwMECwOFgh|ryPLh?= Ml3RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O|goRjJ2OUCwOlc5RC:jPh?=
MDA-MB-231 NV7FbolkTnWwY4Tpc44h[XO|YYm= NXjYelRkOjRiaILz MYTJcohq[mm2aX;uJI9nKGejbX3hMZNm[3KndHHz[UBu\WSrYYTl[EBkdGWjdnHn[UBw\iCQb4TjbEAyKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiboXjcIVieiCjY3P1cZVt[XSrb36gc4YhVm:2Y3igNUBqdnS{YXPlcIx2dGG{IHTvcYFqdiBqTkHJR2QqKGGodHXyJFI1KGi{czDifUBGVEmVQTygTWM2OCB;IECuNFAxPSEQvF2u NWHlSW9kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzhpPkK0PVAxPjd6PD;hQi=>
MOLT-3 M{S3[2Z2dmO2aX;uJIF{e2G7 MYKyOEBpenN? M370cWlvcGmkaYTpc44hd2ZiZ3HtcYEue2WlcnX0ZZNmKG2nZHnheIVlKGOuZXH2ZYdmKG:oIF7veINpKDFiaX6gbJVu[W5iTV;MWE0{KGOnbHzzJIF{e2W|c3XkJIF{KG63Y3zlZZIh[WOldX31cIF1cW:wIH;mJG5wfGOqIEGgbY51emGlZXzseYxieiCmb33hbY4hME5zSVPELUBi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSByLkCwNFYyKM7:TT6= M1;RR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc5Lz5{NEmwNFY4QDxxYU6=
MIAPaCa2 NIHVOVBHfW6ldHnvckBie3OjeR?= MkSxNlQhcHK| NFiyd5pKdmirYnn0bY9vKG:oIHfhcY1iNXOnY4LleIF{\SCvZXTpZZRm\CClbHXheoFo\SCxZjDOc5RkcCBzIHnuJIh2dWGwIF3JRXBiS2F{IHPlcIx{KGG|c3Xzd4VlKGG|IH71Z4xm[XJiYXPjeY12dGG2aX;uJI9nKE6xdHPoJFEhcW62cnHj[YxtfWyjcjDkc41icW5iKF6xTWNFMSCjZoTldkAzPCCqcoOgZpkhTUyLU1GsJGlEPTBiPTCwMlAxODdzIN88UU4> NIjtTVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4QCd-MkS5NFA3Pzh:L3G+
HCT 116 MYTGeY5kfGmxbjDhd5NigQ>? NVP6UZJlOjRiaILz M4HTSmlvcGmkaYTpc44hd2ZiZ3HtcYEue2WlcnX0ZZNmKG2nZHnheIVlKGOuZXH2ZYdmKG:oIF7veINpKDFiaX6gbJVu[W5iSFPUJFEyPiClZXzsd{Bie3Onc4Pl[EBieyCwdXPs[YFzKGGlY4XteYxifGmxbjDv[kBPd3SlaDCxJIlvfHKjY3XscJVt[XJiZH;tZYlvKCiQMVnDSEkh[W[2ZYKgNlQhcHK|IHL5JGVNUVODLDDJR|UxKD1iMD6wNFA4OiEQvF2u NUnuSY95RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzhpPkK0PVAxPjd6PD;hQi=>
MOLT-4 MoiySpVv[3Srb36gZZN{[Xl? NYPHWZJOOjRiaILz M4L5SmlvcGmkaYTpc44hd2ZiZ3HtcYEue2WlcnX0ZZNmKG2nZHnheIVlKGOuZXH2ZYdmKG:oIF7veINpKDFiaX6gbJVu[W5iTV;MWE01KGOnbHzzJIF{e2W|c3XkJIF{KG63Y3zlZZIh[WOldX31cIF1cW:wIH;mJG5wfGOqIEGgbY51emGlZXzseYxieiCmb33hbY4hME5zSVPELUBi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSByLkCwNFc1KM7:TT6= M2TINFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc5Lz5{NEmwNFY4QDxxYU6=
K562 M3yzVmZ2dmO2aX;uJIF{e2G7 MnTENlQhcHK| MofuTY5pcWKrdHnvckBw\iCpYX3tZU1{\WO{ZYThd4UhdWWmaXH0[YQh[2ynYY\h[4Uhd2ZiTn;0Z4ghOSCrbjDoeY1idiCNNU[yJINmdGy|IHHzd4V{e2WmIHHzJI52[2ynYYKgZYNkfW23bHH0bY9vKG:oIF7veINpKDFiaX70doFk\WyudXzhdkBld22jaX6gLG4yUUOGKTDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUCgQUAxNjByMEe0JO69VS5? M{XMUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc5Lz5{NEmwNFY4QDxxYU6=
CCRF-CEM MYjGeY5kfGmxbjDhd5NigQ>? Mmm2NlQhcHK| NVPpNZR3UW6qaXLpeIlwdiCxZjDnZY1u[S2|ZXPy[ZRie2VibXXkbYF1\WRiY3zlZZZi\2Vib3[gUo91[2hiMTDpckBpfW2jbjDDR3JHNUOHTTDj[YxteyCjc4Pld5Nm\CCjczDueYNt\WG{IHHjZ5VufWyjdHnvckBw\iCQb4TjbEAyKGmwdILhZ4VtdHWuYYKg[I9u[WmwIDjONWlETCliYX\0[ZIhOjRiaILzJIJ6KEWOSWPBMEBKSzVyIE2gNE4xODB5NjFOwG0v NULLRWc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzhpPkK0PVAxPjd6PD;hQi=>
DLD1 M3XHU2Z2dmO2aX;uJIF{e2G7 NYnBbIU3OjRiaILz Mnf6TY5pcWKrdHnvckBw\iCpYX3tZU1{\WO{ZYThd4UhdWWmaXH0[YQh[2ynYY\h[4Uhd2ZiTn;0Z4ghOSCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJI52[2ynYYKgZYNkfW23bHH0bY9vKG:oIF7veINpKDFiaX70doFk\WyudXzhdkBld22jaX6gLG4yUUOGKTDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUCgQUAxNjByMEm4JO69VS5? MlLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O|goRjJ2OUCwOlc5RC:jPh?=
A2780 MnPHSpVv[3Srb36gZZN{[Xl? NX7Yc2JUOjRiaILz NHvKUJVKdmirYnn0bY9vKG:oIHfhcY1iNXOnY4LleIF{\SCvZXTpZZRm\CClbHXheoFo\SCxZjDOc5RkcCBzIHnuJIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KG63Y3zlZZIh[WOldX31cIF1cW:wIH;mJG5wfGOqIEGgbY51emGlZXzseYxieiCmb33hbY4hME5zSVPELUBi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSByLkCwNVA{KM7:TT6= NFXsbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4QCd-MkS5NFA3Pzh:L3G+
SUP-T1 M1zUOmZ2dmO2aX;uJIF{e2G7 NI\yZ2ozPCCqcoO= M2qyXmlvcGmkaYTpc44hd2ZiZ3HtcYEue2WlcnX0ZZNmKG2nZHnheIVlKGOuZXH2ZYdmKG:oIF7veINpKDFiaX6gbJVu[W5iU2XQMXQyKGOnbHzzJIF{e2W|c3XkJIF{KG63Y3zlZZIh[WOldX31cIF1cW:wIH;mJG5wfGOqIEGgbY51emGlZXzseYxieiCmb33hbY4hME5zSVPELUBi\nSncjCyOEBpenNiYomgSWxKW0FuIFnDOVAhRSByLkCwNVI1KM7:TT6= NF;6SIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4QCd-MkS5NFA3Pzh:L3G+
Jurkat MnjqSpVv[3Srb36gZZN{[Xl? M{X0bFI1KGi{cx?= Ml;rTY5pcWKrdHnvckBw\iCpYX3tZU1{\WO{ZYThd4UhdWWmaXH0[YQh[2ynYY\h[4Uhd2ZiTn;0Z4ghOSCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO|ZXSgZZMhdnWlbHXhdkBi[2O3bYXsZZRqd25ib3[gUo91[2hiMTDpcpRz[WOnbHz1cIFzKGSxbXHpckApVjGLQ1SpJIFnfGW{IEK0JIhzeyCkeTDFUGlUSSxiSVO1NEA:KDBwMEC1PVUh|ryPLh?= NWLnOZlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzhpPkK0PVAxPjd6PD;hQi=>
In vivo In mice, its oral bioavalability(%F) is 65%, clearance(CL)=41 mL/min/kg, VDss = 3.8 L/kg. In Rats, its oral bioavalability(%F) is 65%, CL=98 mL/min/kg, VDss=4.9 L/kg. In Dogs, its oral bioavalability (%F) is 67%, CL=3.8 mL/min/kg, VDss=1.4 L/kg[1]. In a xenograft tumor model, LY3039478 inhibited N1ICD cleavage and expression of Notch-regulated genes in the tumor microenvironment. The inhibition of Notch cleavage also resulted in the induction of apoptosis in a Notch-dependent xenograft model[2]. In immunodeficient NSG mice xenografted with 769-P CCRCC cells, LY3039478 treatment resulted in significantly increased survival and delayed tumor growth in independent cohorts of mice demonstrating in vivo efficacy in CCRCC[3].

Protocol (from reference)

Cell Research:

[4]

  • Cell lines: K07074 cells
  • Concentrations: 100 nM
  • Incubation Time: 24, 48, 72, 96 h
  • Method:

    K07074 cells were plated to 24-well plates at 105 cell/well. Viability of cells was assessed in quadruplicates at indicated timepoints using the CellTiter-Glo luminescent cell viability assay. To study the effect of the small molecular compounds on K07074 cell growth the compounds or DMSO were added to the growth media 24 h after seeding. The cells were incubated with inhibitors and DMSO as indicated. Cell viability was assessed as described above. Each experiment was carried out in triplicate and at least 3 independent experiments were performed.

Animal Research:

[3]

  • Animal Models: Mice
  • Dosages: 8 mg/kg
  • Administration: oral gavage

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 464.44
Formula

C22H23F3N4O4

CAS No. 1421438-81-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C(=O)NC1C2=CC=CC=C2C3=C(N=CC=C3)N(C1=O)CCO)NC(=O)CCC(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02906618 Completed Drug: LY3039478|Drug: 3C 15N 2H-LY3039478 IV Healthy Eli Lilly and Company October 4 2016 Phase 1
NCT02917733 Completed Drug: LY3039478 Healthy Eli Lilly and Company September 2016 Phase 1
NCT02836600 Active not recruiting Drug: LY3039478 Advanced Solid Tumor Eli Lilly and Company September 9 2016 Phase 1
NCT02518113 Completed Drug: LY3039478|Drug: Dexamethasone|Drug: Placebo T-cell Acute Lymphoblastic Leukemia|T-cell Lymphoblastic Lymphoma Eli Lilly and Company October 1 2015 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Crenigacestat (LY3039478) | Crenigacestat (LY3039478) supplier | purchase Crenigacestat (LY3039478) | Crenigacestat (LY3039478) cost | Crenigacestat (LY3039478) manufacturer | order Crenigacestat (LY3039478) | Crenigacestat (LY3039478) distributor